RANI – rani therapeutics holdings, inc. - class a (US:NASDAQ)
Stock Stats
News
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $9.00 price target on the stock.
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102
Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "buy" rating re-affirmed by analysts at Canaccord Genuity Group Inc.. They now have a $9.00 price target on the stock.
Form S-8 Rani Therapeutics Holdin
Form 10-K Rani Therapeutics Holdin For: Dec 31
Form 8-K Rani Therapeutics Holdin For: Mar 31
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.